Clinical Trial Update: Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating aflibercept (Eylea) for bevacizumab-resistant diabetic macular edema.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• Aflibercept (Eylea) (aflibercept)
• Bevacizumab (Avastin) (bevacizumab)

Snippet

Sponsor: Maisonneuve-Rosemont Hospital | Conditions: Diabetic Macular Edema | Phase 4 | Status: UNKNOWN